From the IMFINZI Official Physician Website that includes references to all adverse reactions to the drug in various trials. The list is lengthy. This is just the reference to lung inflammation data indicating patients had negative respiratory system complications. Interesting dataset. Keep in mind even with the safety profile outlined that references “fatal cases have been reported” the FDA has approved INFINZI for selected medical applications.
“Immune-Mediated Pneumonitis”
“IMFINZI can cause immune-mediated pneumonitis, defined as requiring use of corticosteroids. Fatal cases have been reported. Monitor patients for signs and symptoms of pneumonitis and evaluate with radiographic imaging when suspected. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold IMFINZI for Grade 2 pneumonitis; permanently discontinue for Grade 3 or 4 pneumonitis.”
“In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, pneumonitis occurred in 5% of patients, including Grade 3 (0.8%), Grade 4 (<0.1%), and Grade 5 (0.3%) pneumonitis. Pneumonitis led to discontinuation of IMFINZI in 1.5% of the 1889 patients. In the PACIFIC study, the incidence of pneumonitis (including radiation pneumonitis) was 34%, including Grade 3 (3.4%) and Grade 5 (1.1%) pneumonitis in the IMFINZI arm. In the PACIFIC study, pneumonitis led to discontinuation of IMFINZI in 6% of patients.”
In fairness, as someone noted, trial patients are often in the last stages of illness, with weakened immune systems and are more susceptible to side effect induced death.
Google IMFINZI and click on Official Physician Website link.
G.B.
News 
Market Data 
Discover 
AI
